DBV Technologies S.A. announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors, was appointed as Chairperson of the Boards Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Boards provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges vacancy, effective October 3, 2022. With these changes, the Board comprises 10 members.

Mr. Morris has been a member of DBV Technologies Board and Audit Committee since April 2021. Mr. Morris has served as the Chief Operating Officer and Chief Financial Officer of Humanigen Inc. since August 2020. He currently serves on the board of Aquestive Therapeutics, Univercells S.A. and Humanetics (private).

Mr. Morris has 38 years of professional finance and accounting experience, including 25 years as Chief Financial Officer of public biotechnology companies. Ms. Monges served as a Member of the Companys Board and Audit Committee since May 2019 and Chairperson of the Boards Audit Committee since March 2021. The Board of DBV Technologies has finalized the provisional appointment of a new Independent Director to fill the vacancy left by Ms. Monges and to join the Audit Committee of the Board.

Ms. Daniele Guyot-Caparros joins as a new Independent Director to the Board, subject to ratification by the Companys shareholders at the next annual meeting of shareholders, and as a Member of the Boards Audit Committee. Ms. Guyot-Caparros has a longstanding track record in finance and business operations. She began her career in audit and corporate finance with PricewaterhouseCoopers (PwC) and later joined Rhne-Poulenc-Rorer (later Aventis and Sanofi) where she held several senior finance positions including Chief Financial Officer, Global Research and Development and Chief Financial Officer, Europe, Group Planning.

Ms. Guyot-Caparros also held responsibilities in business development, pricing and portfolio management. In 2008, Ms. Guyot-Caparros became Senior Advisor for Deloitte France to support the development of the Life Sciences and Health Care Industry practice. In addition to in-house experience, Ms. Guyot-Caparros has held positions on the boards of biotechnology and medical technology companies.

She was both a Board Member and Audit Committee Member at Diaxonhit (now Eurobio Scientific), listed on Euronext Growth. Ms. Guyot-Caparros was also Chairperson of the Audit Committee of Supersonic Imagine from July 2018 to September 2019 until its acquisition. From 2013 to 2022, she has been the Chairperson of the Audit Committee of Onxeo, and also served as the Chairperson of its Board of Directors from May 2019 to July 2021.